Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Pfizer, inc. save search
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
Published: 2023-12-06 (Crawled : 04:00) - globenewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
ARVN | News | $32.71 7.95% 7.37% 1.6M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
arv-471 conference breast symposium cancer program
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
Published: 2023-12-05 (Crawled : 19:00) - globenewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
ARVN | News | $32.71 7.95% 7.37% 1.6M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
ibrance program trial
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
Published: 2023-12-04 (Crawled : 21:00) - globenewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
vla15 disease vaccine valneva trial
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Published: 2023-12-01 (Crawled : 22:00) - biospace.com/
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -4.15%
H: 0.0%
C: 0.0%
obesity topline results
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -4.15%
H: 0.0%
C: 0.0%
padcev fda license review bladder cancer treatment application grants
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Published: 2023-11-29 (Crawled : 00:00) - prnewswire.com
ALPMY | $12.15 0.99% 590K
|
Manufacturing
|
| O: 0.66%
H: 0.0%
C: -0.16%
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: 0.0%
women therapy hormone
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
Published: 2023-11-28 (Crawled : 22:00) - globenewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -1.15%
H: 0.0%
C: 0.0%
ARVN | News | $32.71 7.95% 7.37% 1.6M
|
Health Technology
|
| O: 1.72%
H: 4.07%
C: 0.6%
arv-471 breast symposium cancer
Arvinas Announces Oversubscribed $350 Million Private Placement
Published: 2023-11-27 (Crawled : 12:00) - globenewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: 0.81%
H: 0.0%
C: 0.0%
ARVN | News | $32.71 7.95% 7.37% 1.6M
|
Health Technology
|
| O: 2.8%
H: 11.93%
C: 7.54%
Global Synthetic Hormones Market Analysis and Forecast, 2023-2033: Focus on Product Type, Application, Route of Administration, End User, Region, and Competitive Landscape
Published: 2023-11-25 (Crawled : 00:20) - prnewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
| Email alert
Add to watchlist
LLY | News 5 d | $588.27 -0.17% -0.1% 2.1M
|
Health Technology
| Email alert
Add to watchlist
NVS | News 0 d | $95.93 -1.15% 0.0% 1.2M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News 0 d | $96.87 4.13% 220
|
Health Technology
| Email alert
Add to watchlist
global market
Global Vaginitis Therapeutics Market Size Projected to Reach USD 7.20 Billion By 2032, With 8.1% CAGR Growth: Polaris Market Research
Published: 2023-11-23 (Crawled : 15:30) - prnewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News 0 d | $96.87 4.13% 220
|
Health Technology
| Email alert
Add to watchlist
NVS | News 0 d | $95.93 -1.15% 0.0% 1.2M
|
Health Technology
| Email alert
Add to watchlist
reach research global therapeutics market
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - November 21, 2023
Published: 2023-11-21 (Crawled : 17:00) - biospace.com/
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: 0.13%
H: 1.13%
C: 0.93%
conference
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published: 2023-11-17 (Crawled : 04:00) - prnewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
xtandi fda approved cancer treatment
Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market Research
Published: 2023-11-10 (Crawled : 15:00) - prnewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -4.83%
H: 0.0%
C: 0.0%
JNJ | News | $155.4 -0.78% -0.02% 6.4M
|
Health Technology
|
| O: -1.24%
H: 0.0%
C: 0.0%
BMY P | $50.16 0.56% 0.0% 14M
|
Health Technology
|
| O: -3.68%
H: 0.0%
C: 0.0%
ABBV | News | $147.97 1.09% 0.05% 7.2M
|
Health Technology
|
| O: 0.44%
H: 0.0%
C: 0.0%
AZN | News | $63.5 -0.14% -0.14% 6.2M
|
Health Technology
|
| O: -2.88%
H: 0.0%
C: 0.0%
report research market
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-07 (Crawled : 12:00) - globenewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -0.86%
H: 0.98%
C: 0.55%
ARVN | News | $32.71 7.95% 7.37% 1.6M
|
Health Technology
|
| O: -1.33%
H: 4.2%
C: 4.04%
update financial results
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
Published: 2023-11-07 (Crawled : 06:00) - globenewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -0.86%
H: 0.98%
C: 0.55%
conference valneva
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
GNMSF | $313.75 -0.02% 1.4K
|
Health Technology
|
| O: 4.19%
H: 3.29%
C: -1.11%
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: 1.55%
H: 0.0%
C: 0.0%
SNY | News | $46.06 0.17% 0.17% 1.9M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
GMAB | $32.35 0.56% 0.56% 450K
|
Health Technology
|
| O: 0.93%
H: 0.44%
C: -1.37%
BNTX | $101.94 0.59% 0.59% 810K
|
Health Technology
|
| O: 6.29%
H: 3.18%
C: -1.55%
update financial results
Pfizer Reports Third-Quarter 2023 Results
Published: 2023-10-31 (Crawled : 12:00) - biospace.com/
HLN | $8.22 1.23% 0.37% 5.6M
|
n/a
|
| O: 0.87%
H: 0.0%
C: 0.0%
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
BNTX | $101.94 0.59% 0.59% 810K
|
Health Technology
|
| O: 1.59%
H: 0.0%
C: 0.0%
AZN | News | $63.5 -0.14% -0.14% 6.2M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
results
Anti-inflammatory Therapeutics Market Size to Hit US$ 149.5 billion by 2031 | Exclusive Study by Transparency Market Research
Published: 2023-10-30 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.11 3.42% 640
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: 0.0%
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -2.42%
H: 0.0%
C: 0.0%
NVS | News 0 d | $95.93 -1.15% 0.0% 1.2M
|
Health Technology
|
| O: -0.15%
H: 0.25%
C: -0.07%
JNJ | News | $155.4 -0.78% -0.02% 6.4M
|
Health Technology
|
| O: -1.39%
H: 0.79%
C: 0.64%
GSK | News | $36.0 -0.47% 0.06% 2.2M
|
Health Technology
|
| O: 0.03%
H: 0.44%
C: -0.23%
ABBV | News | $147.97 1.09% 0.05% 7.2M
|
Health Technology
|
| O: 2.87%
H: 0.0%
C: 0.0%
SNY | News | $46.06 0.17% 0.17% 1.9M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
research therapeutics study market
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Published: 2023-10-27 (Crawled : 06:00) - prnewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
nefecon nephropathy drug approval treatment application
Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon® Chinese Patient Data and to Hold Conference Calls
Published: 2023-10-27 (Crawled : 01:00) - prnewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
CALT | $17.8004 -0.56% 2.2K
|
Health Technology
|
| O: 2.58%
H: 0.08%
C: -3.42%
nefecon conference kidney presentation chinese week
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
SLDB M | $5.89 72.22% 41.94% 12M
|
Health Technology
SVFD | $3.09 43.72% 30.42% 64M
|
FTEL | $2.04 43.66% 30.39% 110K
|
HPCO 4 | $0.4824 41.92% 29.54% 28M
|
ALGS | $0.6475 -5.06% 26.67% 2.1M
|
Health Technology
GTHX | $3.16 30.58% 23.42% 10M
|
Health Technology
KEQU | News | $22.5 27.62% 21.64% 24K
|
Producer Manufacturing
GSIT | $3.09 27.16% 21.36% 2.2M
|
Electronic Technology
SSKN P | $0.628 25.6% 20.38% 210K
|
Health Technology
GLUE | $3.66 22.82% 18.58% 510K
|
Professional, Scientific, and T...
Your saved searches
Save your searches and get alerts when important news are released.